Systemic analgesic activity and delta-opioid selectivity in [2,6-dimethyl-Tyr1,D-Pen2,D-Pen5]enkephalin

Area of Science:

• Medicinal Chemistry
• Neuroscience
• Pharmacology

Background:

• Opioid peptides like enkephalins modulate pain perception.
• Previous research focused on modifying enkephalin structures to improve receptor binding and in vivo activity.
• The Tyr1 residue in enkephalins is crucial for receptor interaction.

Purpose of the Study:

• To synthesize and evaluate a novel cyclic peptide analog, [2,6-dimethyl-Tyr1,D-Pen2,D-Pen5]enkephalin (2).
• To investigate the impact of replacing the Tyr1 residue with 2,6-dimethyltyrosine (DMT) on opioid receptor potency and selectivity.
• To assess the in vivo analgesic efficacy and systemic activity of the novel peptide compared to its parent compound.

Main Methods:

• Solid-phase peptide synthesis was employed to create the cyclic peptide analog.
• In vitro receptor binding assays were used to determine potency at delta and mu opioid receptors.
• In vivo studies included the hot plate test and writhing inhibition assay to evaluate analgesic effects.

Main Results:

• The novel peptide (2) showed a 10-fold increase in delta opioid receptor potency and a 35-fold increase in mu opioid receptor potency compared to DPDPE (1).
• Substantial delta receptor selectivity was maintained despite increased mu receptor potency.
• The analog (2) demonstrated significantly enhanced in vivo analgesic activity, including potent inhibition of writhing after subcutaneous administration, unlike the parent compound.

Conclusions:

• Replacing Tyr1 with 2,6-dimethyltyrosine (DMT) in [D-Pen2,D-Pen5]enkephalin significantly enhances both opioid receptor binding affinity and in vivo analgesic efficacy.
• The DMT modification improves the systemic bioavailability and therapeutic potential of enkephalin analogs.
• This structural modification represents a promising strategy for developing more potent and orally active opioid-based analgesics.